Esperienze
MD, PhD, Cardiologo e Ricercatore con formazione in Italia e negli Stati Uniti.
Cardiologo interventista, laureato con lode presso l'Università Campus Biomedico di Roma e specializzato con lode in Cardiologia presso l'Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli. Presso il Policlinico Gemelli ho inoltre eseguito una fellowship in cardiologia interventistica ed un dottorato di ricerca. Buona parte del dottorato di ricerca è stato svolto presso l'Università della Florida ed è stato coronato dalla pubblicazione di articoli scientifici come primo autore in alcune delle migliori riviste scientifiche al mondo, come il Lancet. Attualmente molto attivo nel panorama scientifico internazionale, cerco di mettere le mie conoscenze scientifiche al servizio del paziente, svolgendo la mia attività clinica con l'intento di proporre le strategie terapeutiche più aggiornate e all'avanguardia nel settore.
Altro
Su di me
Cardiologo interventista, laureato con lode presso l'Università Campus Biomedico di Roma e specializzato con lode in Cardiologia presso l'Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli. Presso il Policlinico Gemelli ho inoltre eseguito una fellowship in cardiologia interventistica ed un dottorato di ricerca. Buona parte del dottorato di ricerca è stato svolto presso l'Università della Florida ed è stato coronato dalla pubblicazione di articoli scientifici come primo autore in alcune delle migliori riviste scientifiche al mondo, come il Lancet. Attualmente molto attivo nel panorama scientifico internazionale, cerco di mettere le mie conoscenze scientifiche al servizio del paziente, svolgendo la mia attività clinica con l'intento di proporre le strategie terapeutiche più aggiornate e all'avanguardia nel settore.
Aree di competenza principali:
- Cardiologia
- Cardiologia interventistica
Principali patologie trattate
- Coronaropatia ,
- Scompenso cardiaco ,
- Fibrillazione atriale ,
- Dolore toracico ,
- Trombosi coronarica ,
- +5 a11y_sr_more_diseases
Esperienze
Mattia Galli
cardiologo
Patologie trattate
- Coronaropatia
- Scompenso cardiaco
- Fibrillazione atriale
- Dolore toracico
- Trombosi coronarica
- Ipertensione
- Aritmia
- Cardiopalmo
- Insufficienza cardiaca
- Angina
Tirocini
- Policlinico Universitario Agostino Gemelli, Roma
- Shands Hospital, UF Health Jacksonville, Florida, USA
- Bristol Heart Institute, United Kingdom
Pubblicazioni
- Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. The Lancet 2021.
- Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal 2022.
- Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Rev Card 2019
- Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics 2022
- Coronary atherosclerotic phenotype and plaque healing in patients with recurrent acute coronary syndromes compared with patients with long-term clinical stability: an in vivo optical coherence tomography study. JAMA card 2019
- Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. European Heart Journal 2022.
- Bleeding complications in patients undergoing percutaneous coronary intervention. Reviews in Cardiovascular Medicine 2022.
- Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European Heart Journal-Cardiovascular Pharmacotherapy 2022.
- Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease. Thrombosis and Haemostasis 2022.
- High-risk percutaneous coronary intervention: how to define it today?. Minerva Cardioangiologica. 2018
- Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: a critical appraisal. International Journal of cardiology. Heart & Vasculature 2020
- Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace 2020.
- Antiplatelet therapy after percutaneous coronary intervention. Eurointervention 2022.
- Aspirin in primary prevention of cardiovascular disease in the elderly. European Heart Journal-Cardiovascular Pharmacotherapy 2020.
- Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials. Minerva Cardiology and Angiology 2021
- Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: A network meta-analysis. International Journal of Cardiology 2023
- Efficacy and Safety of Lidocaine versus Opioid Analgesics in Acute Coronary Syndromes. Eur Heart J Acute Cardiovasc Care. 2022
- De-escalation of antiplatelet therapy in patients with coronary artery disease: time to change our strategy? Eur J Intern Med. 2022
- Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications. Expert Rev Clin Pharmacol 2022
- Feasibility, effectiveness and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study. Front Cardiovasc Med 2022
- Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs without left ventricular unloading by Impella: a systematic review and meta-analysis. European Heart Journal - Quality of Care and Clinical Outcomes 2022
- Adenosine as adjunctive therapy in patients with acute coronary syndrome: a meta-analysis of 26 randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2022
- Comprehensive functional and anatomic assessment of myocardial bridging: unlocking the Gordian Knot. Front Cardiovasc Med 2022
- Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: time to tackle the Yentl syndrome? Front Cardiovasc Med 2022
- Oral P2Y12 inhibiting therapy in patients with acute coronary syndromes finding the sweet spot. European Heart Journal 2022
- Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antiplatelet (SWAP)-5 study. JACC Cardiovasc Interv 2022
- Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies. Arch Med Sci 2022
- Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease. J Thromb Thrombolysis 2022
- De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?. Front Cardiovasc Med 2022.
- Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis. European Journal of Heart Failure 2022
- Complex percutaneous coronary intervention: what is the role of new-generation scoring balloons?. Minerva Cardiol Angiol 2022
- Etiologic diagnosis of coronary artery aneurysm in a patient with pancreatitis, dacryoadenitis and sialadenitis. European Heart Journal 2022
- A 3-Year Single Center Experience With Left Atrial Pressure Remote Monitoring: The Long and Winding Road. Front Cardiovasc Med 2022
- Optimal Antithrombotic Strategy in NSTE-ACS: Is Age Just a Number?. Revista Argentina de Cardiología 2022
- Atrial fibrillation detection through the modified Microlife blood pressure monitor in patients with cryptogenic stroke: A pilot study. Minerva Cardiol Angiol 2022
- Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens with COVID-19. Eur Heart J Cardiovasc Pharmacother 2022
- Dual versus triple Antithrombotic Therapy for Atrial Fibrillation-ACS/PCI: one size does not fit all. Cardiovascular Revascularization Medicine 2022
- Oral anti-coagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the origami pilot investigation. Minerva Cardiol Angiol 2022
- Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc Med 2021
- The role of antiplatelet therapy in patients with MINOCA. Front Cardiovasc Med 2022
- Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor. JACC Cardiovasc Interv 2021
- Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization. Int J Cardiol 2021
- Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2021
- Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?. European Heart Journal 2021
- Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST elevation myocardial infarction undergoing percutaneous coronary intervention. Eurointervention 2021
- Comparison of Different Stenting Techniques in Left Main Bifurcation Disease: Evidence from a Network Meta-Analysis. J Invasive Cardiol 2022
- Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment. J Thromb Thrombolysis 2021
- Focus on the road to modelling cardiomyopathy in muscular dystrophy. Cardiovasc Res 2021
- Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. J Am Coll Cardiol 2021
- Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis. Eur Heart J Cardiovasc Pharmacother 2021
- Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev Clin Pharmacol 2021
- Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. Curr Opin Cardiol 2021
- Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI. Minerva Cardioangiol 2021
- Reply - Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. Eur Heart J Cardiovasc Pharmacother 2021
- Colchicine in ischemic heart disease: the good, the bad and the ugly. Clin Res Cardiol 2021
- Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2021
- Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2020
- Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. Eur Heart J Cardiovasc Pharmacother 2020
- Colchicine and Risk of Non-Cardiovascular Death in Patients with Coronary Artery Disease: a Pooled Analysis Underling Possible Safety Concerns. Eur Heart J Cardiovasc Pharmacother 2020
- ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study. J Cardiovasc Med (Hagerstown) 2021
- Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin Drug Saf 2021
- Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis. Eur Heart J Cardiovasc Pharmacother 2020
- Potential use of frontal QRS-T angle for sudden death risk stratification in athletes. Minerva Cardioangiol 2020
- Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2020
- Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology. Curr Cardiol Rep 2020
- Telemedicine, Artificial Intelligence and Humanisation of Clinical Pathways in Heart Failure Management: Back to the Future and Beyond. Card Fail Rev 2020
- Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes. Rev Esp Cardiol (Engl Ed) 2020
- Experience of Remote Cardiac Care during Covid-19 Pandemic: the V-LAP™ device in advanced heart failure. Eur J Heart Fail 2020
- Stent thrombosis with dual antithrombotic therapy in AF-ACS/PCI trials: the devil is in the details. JACC 2020
- Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. Trials 2020
- Use of intravascular ultrasound for the assessment and treatment of left main disease. G Ital Cardiol (Rome) 2020
- Very Short vs. Long Dual Antiplatelet Therapy after Second Generation Drug-eluting Stents in 35,785 Patients undergoing Percutaneous Coronary Interventions: a Meta-analysis of Randomised Controlled Trials. Eur Heart J Cardiovasc Pharmacother 2020
- E-cigarettes: a new smoking hype and its potential association with cardiovascular and cerebrovascular risks. European Cardiology Review 2019
- Microvascular dysfunction in Heart Failure with Preserved Ejection Fraction. Front Physiol 2019
- Recurrence of angina after ST-segment elevation myocardial infarction: the role of coronary microvascular obstruction. Eur Heart J Acute Cardiovasc Care 2019
- Antithrombotic therapy in the early phase of NSTE-ACS: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019
- Dual Therapy with DOACs significantly increases the risk of Stent Thrombosis compared to Triple Therapy. Eur Heart J Cardiovasc Pharmacother 2019
- Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Fail 2019
- Dual quantitative coronary angiography accurately quantifies intracoronary thrombotic burden in patients with acute coronary syndrome: Comparison with optical coherence tomography imaging. Int J Cardiol 2019
- Recurrent chest pain: 'what is essential is invisible to the eye?'. Eur Heart J Suppl 2019
- A case of 'resistant' thrombus: all you can hit in very late stent thrombosis. J Cardiovasc Med (Hagerstown) 2019
- Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opin Drug Metab Toxicol 2018
- Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives. Int J Cardiol 2019
- Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. Eur Heart J Cardiovasc Pharmacother 2019
- Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. Eur Heart J Cardiovasc Pharmacother 2019
- How deep is your lesion? Extreme guideliner V3 intubation through RIMA graft to treat a distal left anterior descending artery stenosis. J Cardiovasc Med (Hagerstown) 2018
- High-risk percutaneous coronary intervention: how to define it today?. Minerva Cardioangiol 2018
- Where does inflammation fit?. Curr Cardiol Rep 2017
Formazione
- University of Florida College of Medicine - Jacksonville, Florida, USA
- Università Cattolica del Sacro Cuore
- Università Campus Biomedico di Roma
Premi e riconoscimenti
- https://messina.gazzettadelsud.it/foto/societa/2021/05/23/messina-mattia-medico-in-prima-fila-nella-lotta-alle-malattie-del-cuore-97348f80-9cc2-46d0-b479-f9d5f9073359/
- https://www.tctmd.com/news/another-win-guided-p2y12-therapy-acs-meta-analysis
Indirizzi (4)
Via Antonio Bertoloni 34, Roma
Disponibilità
Questo dottore non offre prenotazioni online a questo indirizzo
Pazienti accettati
- Pazienti senza assicurazione sanitaria
- Pazienti con assicurazione sanitaria
Via Argentieri 30, Messina
Disponibilità
Questo dottore non offre prenotazioni online a questo indirizzo
Pazienti accettati
- Pazienti senza assicurazione sanitaria
Via Giovanni Pastrone 41, Roma
Disponibilità
Questo dottore non offre prenotazioni online a questo indirizzo
Pazienti accettati
- Pazienti senza assicurazione sanitaria
- Pazienti con assicurazione sanitaria
Via le Corbusier, 41-43, Ravenna
Disponibilità
Questo dottore non offre prenotazioni online a questo indirizzo
Pazienti accettati
- Pazienti senza assicurazione sanitaria
Prestazioni e prezzi
-
Visita cardiologica
Da 120 € -
-
Visita cardiologica + elettrocardiogramma (ECG)
Da 135 € -
-
Ecocardiogramma color doppler
Da 120 € -
-
Ecocolordoppler cardiaco
120 € - 150 € -
-
Elettrocardiogramma
Da 50 € -
-
-
Recensioni
44 recensioni
Tutte le recensioni contano e non possono essere rimosse o modificate dai dottori a proprio piacimento.
Scopri come funziona il processo di moderazione delle recensioni.
Per saperne di più sulle opinioni
-
M
Michela
Dottore molto preparato .Ha risposto alle mie domande con professionalità. Mi aspettavo la visita meno breve.....però lo consiglio come cardiologo.
• Ravenna Medical Center • ecocardiogramma color doppler •
-
C
CS
Medico scrupoloso e attento, spiegazioni dettagliate di eventuali esami e diagnosi.
• Ravenna Medical Center • visita cardiologica + elettrocardiogramma (ECG) •
-
S
Sergio
Medico preparatissimo e disponibile. Ha avuto grande professionalità e capacità di comprendere la situazione clinica con molta cura ed empatia. Ringrazio il dott. Galli e lo consiglio vivamente a tutti i futuri pazienti.
• Studio Privato Egidio e Mattia Galli • visita cardiologica •
-
N
Nicola P.
Sono stato dal dottor Galli per un controllo, ho trovato un professionista preparato ma anche cordiale e disponibile, ha risposto alle mie domande e fugato ogni dubbio.
• Studio Privato Egidio e Mattia Galli • Altro •
-
M
MS
Ottimo professionista, competente e preparato. Molto empatico e affidabile.
Ottima visita di controllo cardiologica• Clinica Mater Dei • visita cardiologica •
-
F
Filippo
Dottor Mattia Galli è consigliatissimo. Ottimo collega e professionista. Cordiale e puntuale. Between.
• Altro • Altro •
-
M
MA
Ringrazio il dottor Galli per la disponibilità e puntualità che lo contraddistinguono, consigliatissimo
• Altro • Altro •
-
J
John Wayne
The doctor Mattia was brilliant!! He has such a good knowledge and he knows what he does. He was very precise, careful and so patient to explain and to make very easy to understand even the more complicated sentence. It's soo clear how much love, patience and effort he puts on his work, also how passionate he is about that. What else to say if not " Thank you very much my dear Mattia" when I'll come back in sicily I will organise an other check and I'll come back to your office.
See you soon.• Studio Privato Egidio e Mattia Galli • Altro •
-
C
C C
Medico aggiornato e competente. Ho eseguito la coronarografia con lui e da allora eseguo periodo controlli e mi sento benissimo.
• Clinica Mater Dei • Altro •
-
A
Antonio
Ho avuto il piacere di incontrare questo giovane ma preparatissimo professionista. Mi ha ricevuto con puntualità e garbo nel suo studio. Mi sono sentito sin da subito a mio agio, il dottore e’ stato molto empatico e scrupoloso, mostrando sensibilità e attenzione alla mia condizione. Dopo un paio di mesi di trattamento, ho iniziato a vedere i primi risultati ed ora ho risolto completamente il mio problema. Dopo aver girato diversi medici, finalmente ho trovato il professionista giusto per la mia condizione. Grazie ancora al dr. Galli per tutto il suo supporto ed attenzioni.
• Clinica Mater Dei • visita cardiologica •
Cardiologi nelle vicinanze
Principali patologie trattate